Study identifier:D0540C00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A double-blind, placebo-controlled, randomised, parallel group, phase IIa study to investigate the efficacy, tolerability and safety of 8 doses of AZD8848 administered intranasally once weekly in mild to moderate allergic asthma subjects challenged with an inhaled allergen.
Allergic Asthma
Phase 2
No
AZD8848, Placebo
All
60
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Jan 2016 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
AZD8848 is a new drug that is being tested for the treatment of asthma and allergic rhinitis (hayfever). This study will be in two parts and will include 59 asthmatic patients in total. The first part will investigate the tolerability and safety of AZD8848 while the second part will investigate both the therapeutic effect of AZD8848 and how well patients tolerate the drug.
Location
Location
London, United Kingdom
Location
MANCHESTER, United Kingdom
Arms | Assigned Interventions |
---|---|
Experimental: 1 AZD8848 (30 μg PILOT part and 60 μg MAIN part) | Drug: AZD8848 Nasal spray, solution 0.6mg/ mL. Once weekly for 7 weeks, 8 doses in total. |
Placebo Comparator: 2 Placebo | Drug: Placebo Nasal spray, solution. Once weekly for 7 weeks, 8 doses in total. |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.